Drugs / tenofovir disoproxil fumarate/emtricitabine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04521920 | Nov 2020 → Aug 2021 | HIV infectious disease, opiate dependence | Duke University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tenofovir disoproxil fumarate/emtricitabine | “MOUD) with buprenorphine/naloxone (bup/nx) and oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine through two syringe services programs (SSP)...” PMID 38532395 ↗ Mar 2024 |
| Route | Oral | “oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine” PMID 38532395 ↗ Mar 2024 |